key: cord-0863420-fw479k6i
authors: Barro, Lassina; Nebie, Ouada; Chen, Ming-Sheng; Wu, Yu-Wen; Koh, Mickey BC; Knutson, Folke; Watanabe, Naoto; Takahara, Masayasu; Burnouf, Thierry
title: Nanofiltration of growth media supplemented with human platelet lysates for pathogen-safe xeno-free expansion of mesenchymal stromal cells
date: 2020-05-08
journal: Cytotherapy
DOI: 10.1016/j.jcyt.2020.04.099
sha: 33b0a54c7d77168d17540f1d1842d04303c0d57b
doc_id: 863420
cord_uid: fw479k6i

Abstract Background and aims: Human platelet lysate can replace fetal bovine serum (FBS) for xeno-free ex vivo expansion of mesenchymal stromal cells (MSCs), but pooling of platelet concentrates (PCs) increases risks of pathogen transmission. Herein, we evaluated the feasibility of performing nanofiltration of platelet lysates and determined the impact on expansion of bone marrow-derived MSCs. Methods: Platelet lysates were prepared by freeze-thawing of pathogen-reduced (Intercept®) PCs suspended in 65% storage solution (SPP+) and 35% plasma, and by serum-conversion of PCs suspended in 100% plasma. Lysates were added to the MSC growth media at 10% (v/v), filtered, and subjected to cascade nanofiltration on 35 and 19-nm Planova filters. Media supplemented with 10% starting platelet lysates or FBS were used as the controls. Impacts of nanofiltration on the growth media composition, removal of platelet extracellular vesicles (PEVs), and MSC expansion were evaluated. Results: Nanofiltration did not detrimentally affect contents of total protein and growth factors, or the biochemical composition. The clearance factor of PEVs was over 3 log values. Expansion, of proliferation, membrane markers, differentiation potential, and immunosuppressive properties of cells in nanofiltered media were consistently better than those expanded in FBS-supplemented media. Compared to FBS, chondrogenesis and osteogenesis genes were expressed more in nanofiltered media, and there were fewer senescent cells over six passages. Conclusions: Nanofiltration of growth media supplemented with two types of platelet lysates, including one prepared from pathogen-reduced PCs, is technically feasible. These data support the possibility of developing pathogen-reduced xeno-free growth media for clinical-grade propagation of human cells.

It is now well established that human platelet lysate (also known as "HPL") made from clinical-grade platelet concentrates (PCs) can be used as a xeno-free supplement for propagating human cells, including mesenchymal stromal cells (MSCs), for therapeutic applications. The advantages of HPL include its human origin, which eliminates the immunological and infectious risks possibly associated with the clinical use of animal sera (1) (2) (3) (4) (5) .

In addition, the production of PCs, as performed in blood establishments, is under the supervision of regulatory authorities and thus, meets good manufacturing practice requirements in all advanced economies (4, 5) . The availability of HPL as an alternative supplement for MSCs in vitro expansion, when chemically defined media are not available, is also important considering the expected growth in needs of the regenerative medicine and cell therapy industries (6) . The industrial feasibility of using platelet lysates for clinical-grade expansion of therapeutic human cells is further supported by recent studies which demonstrated that "outdated" PCs, no longer suitable for transfusion, can serve as a suitable source for lysate production, thereby increasing the potential supply (7, 8) .

Ensuring the consistency in quality and safety of platelet lysates is important (4, 5, 9, 10) . Consistency in quality and performance requires the pooling of a sufficient number of PC donations to counterbalance variability among donors (1, 2, 11, 12) . Pooling, however, increases the risk of contamination by blood-borne pathogens, notably viruses, despite donor screening and donation testing for infectious agents, as the sensitivity and selectivity of these two measures have limits (5) . Particular concerns exist with regards to untested emerging viruses, such as West Nile virus, Dengue virus, Zika virus, or coronaviruses, like severe acute respiratory syndrome coronavirus (SARS-CoV) -1 or -2, if they are present in an infectious form in the blood of asymptomatic donors (13) (14) (15) (16) (17) . The ultimate approach to ensure the pathogen safety of pooled lysates, as for any pooled blood products, is by implementing one or two robust and complementary pathogen inactivation or removal treatments (18, 19) . Among those, one robust pathogen removal technology is nanofiltration, a step of filtration using membranes of a few nanometers capable of removing viruses, and possibly other pathogens like prions, based on size-exclusion (20, 21) .

In this study, for the first time, we evaluated the possibility of nanofiltering growth media supplemented with two types of platelet lysates obtained from expired human PCs subjected to psoralen/UVA (Intercept) treatment or left untreated. We also assessed the capacity of using such nanofiltered growth media to expand bone marrow (BM)-MSCs. Finally, we monitored the impacts of nanofiltration on platelet extracellular vesicles (PEVs) present in platelet lysate-supplemented media.

The overall study design is shown in Figure 1 .

The sources of PCs were described previously (22) . Briefly, five apheresis PC donations were collected using the Trima Accel® platelet collection system (TerumoBCT, Lakewood, CO) at the Uppsala University Blood Bank (Uppsala, Sweden) from volunteer donors. The donations were leukoreduced, resuspended in a 65% platelet additive solution (SSP) and 35% plasma, and pathogen-reduced using the Intercept blood system (psoralen/UVA; Cerus Corp., Concord, CA) (23) . After 7 days of storage (to reach the expiry date), the PCs were frozen at −40 °C. In addition, six apheresis PC donations (MCS®+ Mobile Collection System -Haemonetics®, Braintree, MA, USA) suspended in 100% plasma were obtained from the Taipei Blood Center (Guandu, Taipei, Taiwan) after 5 days of storage (to reach the expiry date). All collections were performed following the validated standard operating procedures in place in these two licensed blood establisments and following the recommendations of the suppliers of the apheresis equipment.

To prepare Intercept pathogen-reduced (I)-I-HPL (Figure 1 ), Intercept-treated PC units were thawed (Taipei Medical University, Taipei, Taiwan) in their storage bags at 35±1 °C for approximately 30 min, pooled to obtain a total volume of approximately 1 L, and subjected to two additional freeze/thaw cycles (-80/+35 °C) (22, 24, 25) . I-HPL were then centrifuged (at 6000 xg for 30 min at 22±1 °C) to pelletize the cell debris. The supernatant was recovered, aliquoted (10 mL), and stored at -20 °C until use.

To prepare the serum-converted HPL (SCPL), pooled standard PCs formulated in 100% plasma were activated by calcium chloride (at a final concentration of 23 mM with glass beads) (24) . The mixture was shaken for 1 h at 25±1 °C to activate the coagulation cascade, degranulate the platelets, release growth factors, and convert fibrinogen into fibrin. The fibrin clot attached to the glass beads was readily removed, and the suspension was centrifuged, aliquoted, and frozen as described above.

Dulbecco's modified Eagle's medium (DMEM)/high-glucose medium supplemented with 1% GlutaMax 100X (Gibco, Life Technologies, Grand Island, NY), and 1% penicillin-streptomycin (Gibco, Life Technologies) was mixed with 10% (v/v) I-HPL (2 U/mL heparin added) or SCPL. The mixture was processed as described in figure 1C and table 1. Briefly, the mixture was filtered on 0.22-µm PN 4612 and 0.1-µm PN 4611 filters (Pall Life Science, Ann Arbor, MI), then 400 mL was nanofiltered through 0.01-m 2 Planova 35N 35NZ-010 at a flow rate of 1 mL/minute, and then through 0.01-m 2 Planova 20N 20NZ-010 filters at a flow rate of 0.8 mL/minute (Asahi Kasei Medical, Tokyo, Japan) with monitoring of the protein adsorption at 280 nm, and pressure by an AKTA chromatographic system (GE Healthcare Life Sciences, Freiburg, Germany). The nanofilters were connected to the AKTA system and placed into a Super-CO 150 oven (Enshine Scientific, Taipei, Taiwan) with the temperature maintained at 37 °C during the process (supplementary figure S1). The nanofiltered flow-medium (mNF) was aliquoted and stored at −20°C until use. The starting I-HPL and SCPL were used as controls to specifically detect the impacts of the nanofiltration process on the protein composition, chemical composition, capacity to expand BM-MSCs, and removal of PEVs.

Samples were detected by dynamic light scattering (DLS) to determine the population size and by a nanoparticle tracking analysis (NTA) to determine the size and concentration of EVs. The protein content was measured using a bicinchoninic acid (BCA) protein assay kit (Pierce Biotechnology, Rockford, IL). Brain-derived neurotrophic factor (BDNF), epidermal growth factor (EGF), fibroblast growth factor (FGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF), platelet-derived growth factor (PDGF)-AB, transforming growth factor (TGF)-β, vascular endothelial growth factor (VEGF), and platelet factor 4 (PF4) were quantified by a sandwich enzyme-linked immunosorbent assay (ELISA) technique (DuoSet ELISA; R&D Systems, Minneapolis, MN) as previously described (22, 24) , following the manufacturer's protocol.

We seeded BM-MSCs (American Type Culture Collection, Manassas, VA) in 55-cm 2 dishes and cultured them in the above-described DMEM containing 10% FBS at 37 °C with a 5% CO 2 humidified atmosphere at passage 3. The starting human platelet lysates, I-HPL and SCPLs, and the corresponding nanofiltered media were used for different assessments from passage 4 to passage 10, at a normalized concentration of platelet lysates of 10% (v/v). The growth medium was renewed every 2~3 days.

We measured the PD of BM-MSCs over four passages (Ps). Cells were seeded at 5x10 3 cells/cm 2 in six-well plates with various prepared media.

After reaching 80%~90% confluence, cells were detached with 0.05% trypsin-EDTA (Sigma, St. Louis, MO) and harvested for counting. 10ul of the cells suspension were loaded in the well of the hemocytometer. The cells in the four sets of 16 squares were counted, and then divided by 4 squares to get the mean. The mean was multiplied by 10 4 as a concentration of cells in 1 mL. This concentration was multiplied by the total volume of cells harvested from the well to get the total number of cell (Nf). PD was assessed at the end of each P using the following formula: PD = (log10(Nf) -log10(Ni))/log10 (2) , where Nf denotes the number of cells retrieved at the end of the P, and Ni is the number of cells seeded at the beginning of the P. To calculate the cumulative PD, the number of PDs at the end of each P was added to the PD of the previous P.

Cell viability was evaluated from P4 to P6. We seeded cells (3000 cells/well) in 96-well plates in DMEM supplemented with 10% FBS, or in different human platelet lysates conditions. Viability was assessed after 24 and 72 h using CCK-8 (Sigma). The optical density was measured by a TECAN Sunrise ELISA reader (TECAN, MaÈnnedorf, Switzerland) at 450 nm, and viability was expressed as a percent of FBS.

We performed a flow cytometric analysis using a Sony SA3800 Spectral Analyzer (Sony Biotechnology, Tokyo, Japan). The following cell surface markers (cluster of differentiation (CD) markers) were analyzed at P1 and P4: CD31 (FITC; BD Bioscience San Jose, USA), CD45 (FITC; BD Bioscience), CD73 (APC, clone AD2; BD Bioscience), CD90 (PE; BD Bioscience), CD105 (APC, clone 266; BD Bioscience), and human leukocyte antigen (HLA) DR (APC, clone G46-6; BD Bioscience). Adherent cells were harvested after trypsinization. Cells were washed with PBS and incubated at room temperature for 15 min with different anti-human mouse antibodies, and then incubated on ice for 30 min. Four percent paraformaldehyde (PFA) in phosphate buffer was used to fix cells after incubation under previously defined conditions. PFA was discarded after centrifugation (300 xg for 5 min), and cells were re-suspended in PBS for the flow cytometric analysis.

After four Ps in different experimental media, we assessed the differentiation potential of expanded MSCs at P8 into adipogenic, osteogenic, or chondrogenic lineages as described before (22) . To evaluate adipogenesis, BM-MSC cells were seeded at a density of 60,000 cells per well in six wells/plate. Adipogenesis was induced by adding 0. 

Samples were collected at day zero of differentiation induction (d0), d7, d10, d14, and d21 to check expressions of genes involved in differentiation:

PPARG and ADIPOQ genes for adipogenesis; SOX9 and RUNX2 genes for chondrogenesis; and SPP1 and RUNX2 genes for osteogenesis. Total RNA was extracted using a RNeasy Micro Kit (Qiagen, Valencia, CA). Complementary (c)DNA synthesis was performed using 1 µg of total RNA, random primers, and the Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA) at 42 °C for 50 min in a final volume of 20 µL. Polymerase chain reaction (PCR) amplification was performed using QuantiTect SYBR Green PCR Mix (Qiagen). Primer sequences, annealing temperatures, and PCR cycling conditions are described in Table 2 . β-2M mRNA was used as an internal control. The -ΔΔCt (threshold cycle) was defined as - 

At P7, we seeded cells at 5x10 3 cells/cm 2 in six-well plates in the various media prepared. Media were refreshed after 48 h. Cells were maintained for 3 days of culture, then the medium was collected and centrifuged (6000 xg for 10 min), and the supernatant was retained for an EV analysis and for immunosuppression assessment.

We isolated peripheral blood mononuclear cells (PBMCs) from whole blood collected from four healthy donors. PBMCs were stimulated with mitogen phytohemagglutinin (PHA) (Gibco Life Technologies) in different culture media (RPMI-1640 supplemented with 10% FBS or HPL fractions) for 4 days at 37 °C with a 5% CO 2 humidified atmosphere. Viability was assessed using CCK-8 for PBMCs cultured alone or PBMCs in medium from BM-MSC culture mixed v/v with new medium, or co-cultured with BM-MSCs, using a 10:1 ratio of PBMCs to BM-MSCs, for 3 days.

The percent proliferation inhibition of BM-MSCs was calculated from this formula: I = (1 -(ODpbmc)/ODcc)  100 (CC, PBMC culture with BM-MSCs). Different culture conditions media were collected and used for interleukin (IL)-6, IL-10, and tumor necrosis factor (TNF) assessments by ELISA methods.

We performed a senescence assay with BM-MSCs cultured as cells counted from P8 to P10. After reaching 80%~90% confluence, cells were trypsinized and harvested for counting. A second six-well plate was used for histochemical staining of senescent cells. After washing with PBS, cells were fixed and stained using an X-gal solution (26) . The six-well plates were next incubated overnight at 37 °C without CO 2 . The blue dye formed by senescence-associated β-galactosidase (β-gal) cells was observed under an optical microscope (DMI8 microscope, Leica Wetzlar, Germany), and images were captured. Ten random fields, each from three different BM-MSC culture conditions and control cultures, were used to calculate the senescence ratio.

All data were from three independent experiments and are presented as the mean ± standard deviation (SD). Statistical analyses were performed using GraphPad Prism software vers. 6.0 (GraphPad Software, La Jolla, CA). An analysis of variance (ANOVA) and t-test were used for comparison, and differences were considered significant at p < 0.05.

Intercept-treated apheresis PC donations were 180 mL to 220 mL and had a mean platelet count of 3x10 11 ± 0.26 platelets/unit. Standard apheresis PC were 230 mL to 260 mL and with a platelet count of 5.3x10 11 ± 1.2 platelets/unit. The PCs were used to prepare I-HPL and SCPL and added at a 

The chemical compositions of different media are summarized in Table 3 . The mNF-IHPL and mNF-SCPL had significantly lower levels of ferritin (3±1 and 4.33 ± 1.15 ng/mL, respectively), calcium (Ca) (3.03 ± 0.32 and 11.67 ± 1.23 mg/dL), and phosphorus (5.43 ± 0.31 and 0.83 ± 0.15 mg/dL) compared to I-HPL or SCPL (p<0.05, p<0.0001 or p<0.05 and p<0.01, respectively). Similar significant differences were found for ferritin, magnesium (Mg), Ca, iron (Fe), phosphorus, and potassium (K) for I-HPL and SCPL and their derived nanofiltered medium compared to FBS. Total protein and albumin contents were significantly less in I-HPL and mNF-IHPL compared to FBS, SCPL, and mNF-SCPL (p<0.05), as expected.

Growth factor contents are shown in Figure 2 . There were significant decreased in BDNF, EGF, PDGF-AB, TGF-β, and VEGF contents in the 10% I-HPL-medium between before and after nanofiltration (from 4284 to 106 pg/mL p<0.001; 414 to 292 pg/mL p<0.001; 8693 to 2845 pg/mL p<0.001; 4465 to 3121 pg/mL p<0.05; and 50 to 38 pg/mL p<0.05, respectively). Similar decreases were found in the 10% SCPL-medium before and after nanofiltration (from 3586 to 911 pg/mL p<0.001; 86 to 48 pg/mL p<0.01; 5544 to 3846 pg/mL p<0.001; 3617 to 2657 pg/mL p<0.01; and 159 to 95 pg/mL p<0.05, respectively). In contrast, no significant difference was found in HGF or IGF contents in I-HPL supplemented media, regardless of whether or not they were nanofiltered.

Particle sizes and concentrations of PEVs in the various media as determined by DLS and NTA, respectively, are shown in Table 4 . Figure 3A and 3B show the size distribution at different preparation steps of the nanofiltered medium. Concentrations of PEVs significantly decreased between the unfiltered and the 20N nanofiltered media (5.12  10 11 to 4.79  10 8 , p<0.01 for I-HPL; 9.17  10 11 to 1.15  10 9 , p<0.001 for SCPL). Nanofiltration removed mostly PEVs as indicated by the difference between 0.22-µm filtration and 20N nanofiltration (4.65  10 11 to 4.79  10 8 p<0.01 for I-HPL and 8.89  10 11 to 1.15  10 9 p<0.05 for SCPL).

The typical morphology of BM-MSCs which expanded from P4 to P7 is shown in Figure 4A 

Cell surface markers at P4 are shown in Figure 5A . All cultures expressed the MSC markers of CD73, CD90, and CD105. However, CD105 expression was <95%. TCD105 expression was high (>95%) at P7 as shown in Figures 5B and 4C . CD31 and CD45, primitive hematopoietic progenitors and endothelial cells, were <5% in all media. HLA DR expression was <5% in all media supplemented with human platelet lysates, and slightly higher in FBS medium (8%~9%).

The differentiation capacity of BM-MSCs into osteoblasts, chondrocytes, and adipocytes was effective under all conditions (Fig. 6 ). Lipid droplet accumulation (adipogenesis) was significantly higher in cells expanded in medium supplemented with FBS compared to I-HPL, mNF-IHPL, and mNF-SCPL (p<0.05, p<0.0001, and p<0.0001, respectively). No significant difference was found between SCPL and FBS. Significant differences were found between I-HPL and mNF-IHPL (p<0.05), and between SCPL and mNF-SCPL (p<0.001). ECM formation during chondrogenesis, as assessed by GAG, was significantly higher in all human platelet lysates supplements (p<0.01) compared to FBS supplementation. Calcium deposition, a characteristic of osteogenesis, was significantly higher (p<0.0001) in all platelet lysate-supplemented media than in FBS-supplemented media. Significant differences were found between I-HPL and mNF-IHPL (p<0.0001), and between SCPL and mNF-SCPL (p<0.0001).

Expressions of ADIPOQ and PPARG (adipogenesis) as quantified by a qPCR at days 7, 10, and 14 were lower (p<0.0001) in all media supplemented with platelet lysates compared to those supplemented with FBS (Fig. 6q, r) . No significant difference was observed in ADIPOQ expression among cells expanded in platelet lysate-supplemented media. However, a significant difference was found in PPARG expression (p<0.001) when comparing I-HPL-and mNF-IHPL-supplemented media. In general, multiples of expression of both genes increased from days 7 to 10. The expression had decreased at day 14 compared to day 10. Expressions of RUNX2 and SOX9 (chondrogenesis) increased from days 7 to 14 and had decreased by day 21 (Fig. 6t, u) . Multiples of expression of RUNX2 were significantly higher (p<0.01) when using mNF-IHPL compared to other supplements, followed by mNF-SCPL (p<0.05) at day 7. RUNX2 was more highly expressed in human platelet lysates media than in FBS. From days 7 to 14, multiples of expression of SOX9 were significantly higher in I-HPL-(p<0.0001) and SCPL-supplemented media (p<0.001) than in FBSsupplemented media. RUNX2 and SPP1 genes expression (osteogenesis) showed significant (p<0.0001) increases at day 14 with the platelet lysate media compared to FBS (Fig. 6w, x) . Low expressions of both genes were observed when cells were in FBS-supplemented medium.

We then examined the release of EVs by BM-MSCs cultured for 72 h in media that was nanofiltered or not ( Table 4 , Fig. 7) . The NTA analysis did not show a significant difference in EV concentrations in FBS-based conditioned medium compared to conditioned media supplemented by human platelet lysates.

Results of the assessment of BM-MSCs immunosuppressive activities are shown in Figure 8 . BM-MSC viability in coculture was similar under all culture conditions (Fig. 8a) , apart from mNF-IHPL medium where the viability was lower compared to I-HPL (p<0.01). PBMC proliferation under 2% PHA activation was similar in all supplements, except when using SCPL supplementation, for which cells had higher viability than when using FBS (p<0.0001). Differences were observed in PBMCs cultured with medium from BM-MSC culture (p<0.01for FBS vs. I-HPL, and p<0.001 for FBS vs. mNF-IHPL). The inhibition ratio of BM-MSC proliferation in coculture (Fig. 8c ) was significantly higher in media supplemented with FBS compared to I-HPL (p<0.05) and mNF-IHPL (p<0.01). The IL-6 concentration was higher in all cocultures compared to BM-MSCs alone or to activated PBMCs. However, secretion was higher in mNF-IHPL (p<0.0001) and mNF-SCPL (p<0.0001) compared to FBS. IL-10 secretion was similar in all media supplements when PBMCs were activated by PHA (Fig. 8e) . The secretion level of TNF was very high in the PBMC/PHA culture condition, with particularly high levels in mNF-IHPL and mNF-SCPL media compared to FBS (p<0.0001), I-HPL (p<0.0001), and SCPL (p<0.0001) media. There was less TNF in coculture conditions and when PBMCs were cultured in BM-MSC culture medium. However, lower TNF secretion was found in cocultures and PBMC culture in BM-MSC medium.

Cell morphologies from P8 to P10 are shown in Figure 9a -9o. There were significantly (p<0.0001) more senescent cells in FBS-supplemented cultures than others as shown by the ratio of senescence-associated β-galactosidase (SA-β-gal)-positive cells (Figure 9q ). This ratio was higher in mNF-IHPL compared to I-HPL (p<0.0001), and in mNF-SCPL compared to SCPL (p<0.0001).

The possibility of using platelet lysate supplements in place of FBS provides a valuable xeno-free option for propagating human cells used for cell therapy procedures (2) (3) (4) (5) 10) . Pooling of a minimum number of allogeneic PC donations, is needed to ensure platelet lysate consistency in quality and performance (5, 27, 28) , increases viral risks (5, 19, 29) . Lysates can now be prepared from PC donations that have been pathogen-reduced by psoralen/UVA (30, 31) or UV (32) treatments, without detrimentally affecting the MSC expansion capacity compared to FBS, thereby providing an important step forward in virus safety. Application of pathogen reduction by psoralen/UVA treatment after platelet lysis (33) , and gamma-irradiation of pooled HPL (19) may also be alternative feasible approaches recently evaluated. However, all pathogen-reduction technologies have limits in their capacities, and pooling increases the risk of contamination by (a) window period donations, (b) viruses that are not tested for, (c) emerging infectious agents, and potentially (d) prions (13) (14) (15) (16) (17) 19) . These reasons make the implementation of "orthogonal" pathogen-reduction treatments of platelet lysates, as done for a long time in the plasma fractionation industry (34, 35) , highly desirable as stressed in recent publications (5, 19, 29) . We recently showed the feasibility of preparing platelet lysates subjected to psoralen/UVA and solvent/detergent (22) , a treatment that is highly efficient against lipid-enveloped viruses (34) (35) (36) . However, combining these two treatments may not eliminate the risk of transmission of non-enveloped viruses (37, 38) , such as hepatitis A virus, hepatitis E virus, and parvovirus B19, justifying exploration for other pathogen-reduction procedures.

Nanofiltration is recognized as being a very robust process for removing by a size-exclusion mechanism over 4 log levels of viruses that are larger than the pore-size of the membrane used. Due to its reliability and robustness, nanofiltration is widely used in the plasma fractionation and biotech industries to ensure the safety of licensed biologicals made from mammalian sources against pathogens (20, 21, 39) . Virus removal achieved by both the 35-and 20-nm nanofilters has been shown to be robust including for known small viruses such as parvovirus B19 using a wide range of filtration conditions (20, (39) (40) (41) . Nanofiltration on small-pore-size filters of ≤35 nm was also found in experimental models to be effective at removing several log levels of prions (42, 43) . It was therefore relevant to assess whether nanofiltration can be considered as a means to improve HPL virus safety.

The main purpose of this study was therefore to determine whether nanofiltration can be considered by manufacturers to improve the pathogen safety of pooled allogeneic human platelet lysates used as growth medium supplements for MSC expansion in vitro. To answer this question, we used two types of platelet lysates that are representative of those currently used by the cell therapy industry (10) . One was prepared from non-pathogenreduced PCs suspended in 100% plasma. Platelet lysates from this source material were serum-converted by calcium chloride activation, as described by others before (1), to remove fibrinogen and avoid the need for heparin addition during cell culture (10) . Removal of fibrinogen, and other highmolecular-mass coagulation factors during fibrin formation, from this lysate made from PCs in 100% plasma can also facilitate the nanofiltration process, since fibrinogen solutions are known to be difficult to nanofilter on 20-nm membranes (44) . The other platelet lysate was produced from PCs subjected to psoralen/UVA pathogen reduction, and suspended in a 65% SSP+ additive solution and 35% plasma. This lysate was not serumconverted, as we speculated that the partial removal of plasma, resulting in a major decrease in the total protein content, could facilitate the nanofiltration process. Both HPLs were prepared from outdated PCs collected by apheresis due to availability of this material for our study.

However, it has been shown that PCs prepared from buffy coats isolated from whole blood donations are equally effective as source material to prepare HPL for human cell propagation (5, 10) . Nanofiltration was directly carried out on growth medium supplemented with 10% of these two platelet lysates. Medium nanofiltration was selected because (a) filtering the raw platelet lysates could result in nanofilter clogging, and (b) it eliminates risks of contaminating cell cultures by adventitious pathogens that could originate from operators or raw materials (45) , as evidenced by the commercial availability of dedicated medium filters following viral contamination of recombinant proteins (46, 47) .

We found that nanofiltration largely preserved the total protein and biochemical compositions of the growth media supplemented with these two types of platelet lysates. The reasons for the decreases in the contents of BDNF, PDGF-AB, and PF4 due to the nanofiltration process were unclear considering their low molecular masses, but could have been due to nonspecific adsorption onto the nanofilters, as was observed before with hydrophobic chromatographic media (48) . However, the overall concentrations of growth factors evaluated remained within the expected range of platelet lysate-supplemented media (3, 10, 49) . A DLS analysis of the nanofiltered media showed the disappearance of the main PEV population of approximately 70 nm. The possibility of preparing PEV-depleted media for MSC culture is of interest as this avoids or decreases the risks of contaminating MSC-EVs used for clinical applications by EVs originating from growth medium supplements like FBS or platelet lysates (50) (51) (52) .

Two main methods of EV depletion have been reported so far: high-speed ultracentrifugation and chemical precipitation (53, 54) . Our data suggest that nanofiltration on 20-nm nanofilters may represent a powerful alternative approach for EV removal from growth media, although further evaluation remains needed to establish the robustness of such removal.

The BM-MSCs expanded in nanofiltered platelet lysate media were better than those in FBS-supplemented media, and they maintained their stem cell phenotype, fulfilling ISCT criteria (55) . CD31, a platelet-endothelial cell marker, was found negative, thereby demonstrating that the use of human platelet did not modify the lack of expression of this marker in BM-MSCs (56, 57) . Over long-term culture (P8 to P10), BM-MSCs expanded in nanofiltered media had an increasing ratio of senescent cells, possibly consistent with the removal of PEVs, as suggested by other studies (54, 58) .

Nevertheless, this ratio was still less than that found in cells expanded in FBS supplements.

BM-MSCs expanded in all platelet lysate-supplemented media could well differentiate into three lineages. The adipogenic differentiation capacity was less than that of FBS-expanded cells, as indicated by expressions of the ADIPOQ and PPARG genes that are critical for this differentiation (59) .

Chondrogenesis differentiation was more effective in media supplemented with platelet lysates, as shown by the expressions of RUNX2 and SOX9, which are associated with cartilage formation. Genes expression profiles were consistent with previous studies showing upregulation during the ECM formation phase, thereafter followed by downregulation during the ECM maturation phase (22, 60) .

Upregulation of the RUNX2 and SPP1 genes, which was more pronounced in all platelet lysate-expanded cells, reflects the successful capacity of BM-MSCs to differentiate into osteocytes. The relatively lower expression in nanofiltered growth media could possibly be linked in part to a decrease of FGF content, as this growth factor plays a key role in osteogenesis by activating RUNX2, which regulates bone formation and growth, and participates in the anabolic function of osteoblasts (61, 62) . Gene expression data obtained here are consistent with previous reports on the stronger stimulation of chondrogenic and osteogenic differentiation using human platelet lysates than FBS (22, 30, 63) .

Data showed inhibition of TNF and IL-10 secretions, as well as suppression of PBMC proliferation in coculture conditions. Moreover, a similar immunosuppressive effect was found in PBMCs cultured in medium recovered from BM-MSC culture. Our immunosuppression data of BM-MSCs were similar to previous studies (22, 64) , which identified that TNF induces suppression of PBMC proliferation by triggering an MSC-mediated immunoregulatory function (65) . TNF activates transcription factors to produce IL-6 (66) as shown in coculture.

It should be kept in mind that PEV depletion, as obtained by nanofiltration, may have detrimental effects on in vitro cell growth, as well as viability and immunosuppressive effects (53, 54, 58, 67) . BM-MSCs expanded in the two nanofiltered media exhibited lower proliferation rates, less viability, and higher ratios of senescent cells compared to their non-nanofiltered counterparts, possibly due to the removal of PEVs. Nevertheless, the performance of BM-MSC expansion of nanofiltered media was still superior to that of the FBS-based medium. Interestingly, concentrations of EVs released by BM-MSCs were found to be similar in all conditions, regardless of whether the medium was depleted of PEVs by nanofiltration or not, suggesting that using a PEV-depleted medium does not decrease or interfere with the release of EVs by MSCs.

Implementing a nanofiltration process has obvious advantages for optimal pathogen safety of HPL-supplemented growth media against blood-borne, as well as adventitious, viruses. Pathogen reduction of cell culture media prevents virus contaminations resulting from potential failures in the safety of raw materials and in good manufacturing practices, as has been seen in the biotech industry (68, 69) . Technical options for the prevention of contamination of growth media include high-temperature short-time treatment and ultraviolet-C irradiation (70) or virus-filtration processes (71, 72) .

Conversely, nanofiltration of HPL-growth media implies specific measures at production scale including the creation of a dedicated virus-free area and specific working procedures intended to avoid the risks of downstream contaminations, as in the case, for instance, in the plasma fractionation industry. Finally, scalability and cost of the nanofiltration process are other factors to consider. Under our experimental conditions, we could nanofilter approximately 400 mL of media on 0.01m 2 nanofilters, implying that 40 L of media could be nanofiltered using commercially available 1m 2 nanofilters within eight to ten hours. Advantages of nanofiltration over S/D treatment include (a) relative simplicity of the filtration process, (b) no requirements to remove toxic chemicals and (c) removal of non-lipid enveloped viruses and, possibly, prions.

One limitation of our study is the lack of virus removal experiments to demonstrate the actual clearance factor of viruses achieved with the nanofiltration sequence used. Such studies should indeed be performed by HPL-media suppliers or users, following existing guidelines, once exact manufacturing conditions are defined. However, there is ample information in the literature to support the robustness of nanofiltration at removing viruses and other pathogenic agents larger that the membrane pore-size (20, 21, 39) . In particular, nanofiltration of plasma protein products using filters with a pore size of 35 or 19 nm provides a robust removal of emerging blood-borne viruses. For instance, clearance factor of over 4 log 10 of West Nile virus, Dengue virus, and Zika virus and model viruses with a size of approximately 40-50nm, can readily be achieved when filtering various protein solutions on 35 or 19 nm-filters identical to those used in this study (39, 73) . Consistent removal of smaller viruses, like hepatitis A virus (27 nm), human parvovirus B19 (23-28 nm), or human poliovirus-1 (30 nm), has also been found using the 19-nm nanofilter (21, 40, 74) . An extensive data collection from the Plasma Protein Therapeutic Association, reflecting 20 years of experience in the manufacture of human plasmaderived proteins, "substantiates the effectiveness and robustness of nanofiltration in virus removal" (75). The current SARS-CoV-2 pandemic illustrates the theoretical risk of virus contamination of ancillary material essential to cell therapy procedures. It is, therefore, critical to implement robust in-process virus reduction procedures capable of counterbalancing efficiently the virus risks associated with the source material or arising from possible air-borne contamination. Coronaviruses, which have a size of close to 80 to 120 nm, should be readily removed by nanofilters with a pore size of 35 or 19 nm if present in the cell culture medium.

In conclusion, although the performance of the HPL was partially affected by nanofiltration, our data support the technical feasibility of applying a dedicated pathogen-removal nanofiltration step of growth media supplemented with two standard human platelet lysates. In particular, nanofiltration can be applied to lysates derived from pathogen-reduced PCs, making the end-product for cell expansion subjected to two complementary reduction treatments. The robustness of such nanofiltration process to remove viruses and prions should be validated by HPL users on a case-by-case basis using relevant experimental models and following guidelines. The possibility of implementing nanofiltration and double pathogen-reduction steps may turn out to offer a favorable cost/benefit ratio for the future industrial development of pooled human platelet lysates as safe supplements for the ex vivo propagation of MSC-based medicinal products. C, D, and E respectively represent cell viability at passages 4, 5, and 6 in 24-and 72-hours culture conditions. Viability was assessed using the CCK-8 reagent, and the OD was measured by an ELISA reader at a 450-nm wavelength. FBS culture used as the standard was set to 100%. Values are expressed as the mean ± SD; N=3. * p<0.05; ** p<0.01; *** p<0.001, **** p<0.0001; ns, no significant difference. * FBS or 10% HPL in DMEM vs HPL filtered; # I-HPL vs mNF-IHPL; + SCPL vs mNF-SCPL. *, #, or + p < 0.05; **, ##, or ++ p < 0.01; ***, ###, or +++ p < 0.001; ****, ####, or ++++ p < 0.0001.

Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow

Human platelet lysate current standards and future developments

Preparation, quality criteria, and properties of human blood platelet lysate supplements for ex vivo stem cell expansion

International Forum on Gmp-grade human platelet lysate for cell propagation: summary

Production and quality requirements of human platelet lysate: a position statement from the working party on cellular therapies of the international society of blood transfusion

Multilineage potential of adult human mesenchymal stem cells

Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells: present and future

Comparison of human platelet lysate alternatives using expired and freshly isolated platelet concentrates for adiposederived stromal cell expansion

Gaps in the knowledge of human platelet lysate as a cell culture supplement for cell therapy: A joint publication from the AABB and the International Society of Cell Therapy

Human platelet lysate: Replacing fetal bovine serum as a gold standard for human cell propagation?

Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells

Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue

Zika virus: a new challenge for blood transfusion

Zika virus and the never-ending story of emerging pathogens and transfusion medicine

West Nile Virus in Europe and Safety of Blood Transfusion

Dengue Virus and Blood Transfusion

Viral load of SARS-CoV-2 in clinical samples

CPMP Note for guidance on plasma -derived medicinal products

Strategies toward virus and prion safe human platelet lysates

Nanofiltration of plasma-derived biopharmaceutical products

The role of nanofiltration in the pathogen safety of biologicals: an update

A double-virally-inactivated (Intercept-solvent/detergent) human platelet lysate for in vitro expansion of human mesenchymal stromal cells

Raw materials of biological origin for the production of cell-based and gene therapy medicinal products -European Pharmacopoeia eu/en/pheur-9th-edition

Four types of human platelet lysate, including one virally inactivated by solvent-detergent, can be used to propagate Wharton jelly mesenchymal stromal cells

Standardizing the freeze-thaw preparation of growth factors from platelet lysate

Evaluating Wharton's jelly-derived mesenchymal stem cell's survival, migration, and expression of wound repair markers under conditions of ischemia-like stress

Preparation of pooled human platelet lysate (pHPL) as an efficient supplement for animal serum-free human stem cell cultures

A highly standardized and characterized human platelet lysate for efficient and reproducible expansion of human bone marrow mesenchymal stromal cells

Viral safety of human platelet lysate for cell therapy and regenerative medicine: Moving forward, yes, but without forgetting the past

Expired and Pathogen-Inactivated Platelet Concentrates Support Differentiation and Immunomodulation of Mesenchymal Stromal Cells in Culture

Culture of human cell lines by a pathogen-inactivated human platelet lysate

Pathogen reduction through additive-free short-wave UV light irradiation retains the optimal efficacy of human platelet lysate for the expansion of human bone marrow mesenchymal stem cells

Effects of amotosalen treatment on human platelet lysate bioactivity: A proof-of-concept study

Reducing the risk of infection from plasma products: specific preventative strategies

Burnouf T: Modern plasma fractionation

Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies

Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma

Parvovirus B19 Passive Transmission by Transfusion of Intercept(R) Blood System-Treated Platelet Concentrate

Robustness of nanofiltration for increasing the viral safety margin of biological products

Removal of small viruses (parvovirus) from IgG solution by virus removal filter Planova (R) 20N

Microscopic visualization of virus removal by dedicated filters used in biopharmaceutical processing: Impact of membrane structure and localization of captured virus particles

Manufacture of plasma-derived products in France and measures to prevent the risk of vCJD transmission: precautionary measures and efficacy of manufacturing processes in prion removal

Current strategies to prevent transmission of prions by human plasma derivatives

Biochemical characterization, stability, and pathogen safety of a new fibrinogen concentrate (fibryga((R)))

Adventitious Viruses Detected in Biopharmaceutical Bulk Harvest Samples over a 10 Year Period

Supplement: Upstream Virus Safety: Protect Your Bioreactor by Media Filtration

Protection of bioreactor culture from virus contamination by use of a virus barrier filter

A virally inactivated functional growth factor preparation from human platelet concentrates

Removal process of prion and parvovirus from human platelet lysates used as clinical-grade supplement for ex vivo cell expansion

Therapeutic application of mesenchymal stem cells derived extracellular vesicles for immunomodulation

Extracellular microvesicles as new industrial therapeutic Frontiers

Extracellular Vesicles As Nanomedicine: Hopes And Hurdles In Clinical Translation

Fetal bovine serum-derived extracellular vesicles persist within vesicle-depleted culture media

Depleting extracellular vesicles from fetal bovine serum alters proliferation and differentiation of skeletal muscle cells in vitro

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement

CD31: beyond a marker for endothelial cells

Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells

Extracellular vesicle-depleted fetal bovine and human sera have reduced capacity to support cell growth

The bone marrow-derived stromal cells: commitment and regulation of adipogenesis

Regulation of bone and cartilage development by network between BMP signalling and transcription factors

Fibroblast growth factor 2 induction of the osteocalcin gene requires MAPK activity and phosphorylation of the osteoblast transcription factor, Cbfa1/Runx2

The roles of signaling pathways in bone repair and regeneration

Human periodontal ligament stem cells on calcium phosphate scaffold delivering platelet lysate to enhance bone regeneration

IFN-γ and TNF-α pre-licensing protects mesenchymal stromal cells from the pro-inflammatory effects of palmitate

Human mesenchymal stromal cells modulate T-cell responses through TNF-α-mediated activation of NF-κB

IL-6 in inflammation, immunity, and disease

Exosomes in fetal bovine serum dampen primary macrophage IL-1β response to lipopolysaccharide (LPS) challenge

Virus Safety of Biopharmaceuticals -Absence of evidence is not evidence of absence

Mouse Minute Virus (MMV) Contamination-A Case Study: Detection, Root Cause Determination, and Corrective Actions

Integrated viral clearance strategies -reflecting on the present, projecting to the future

Supplement: Upstream Virus Safety: Protect Your Bioreactor by Media Filtration

Protection of bioreactor culture from virus contamination by use of a virus barrier filter

A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity

Viral safety characteristics of Flebogamma DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin

BM-MSC) immunosuppressive activities: a) BM-MCS 72 h culture viability at passage 8 and BM-MSCs mixed with peripheral blood mononuclear cell (PBMC) (coculture) viability; b) PBMC culture viability assessment for 72 h culture (PBMC phytohemagglutinin (PHA): PBMC culture in RPMI1640 supplemented with 2% PHA

FBS OD was used as the reference and represented 100% of viability; c) inhibitory effects of PBMCs on BM-MSC proliferation in coculture; d) interleukin (IL)-6 measurement by an ELISA method from different experimental culture media (BM: BM-MSC culture media

coculture culture media); e) IL-10 measurement by an ELISA; f) tumor necrosis factor (TNF) measurement by an ELISA. ND, not detectable. Values are expressed as the mean ± SD

001, **** p<0.0001; ns, no significant difference

Senescence assay: bone marrow-derived mesenchymal stromal cell (BM-MSC) senescent cell staining by X-Gal reagent at passages 8 (a-e)

counting: cells nb., cell numbers after trypsinization, harvested cells were counted and seeded for the next passage; Senes. cells, senescent cells counted in ten microscopic fields and total numbers of cells in the same ten microscopy fields; q) senescence ratio obtained from cell counting. Arrow indicating senescent cell

We thank the Uppsala University blood bank and Taipei Blood Center (Guandu, Taiwan) for supplying platelet concentrates. We acknowledge Prof.Rita Yen-Hua Huang for providing BM-MSCs. We also thank Wilson Fang-Wei Hsiang for FCM technical support. This study was partially funded by Asahi Kasei Medical (Tokyo, Japan), through a research collaboration agreement with Taipei Medical University. The sponsor played no role in data collection, analysis, or interpretation, manuscript writing, or the decision to submit the article for publication. 

* FBS vs HPL; # I-HPL vs mNF-IHPL; + SCPL vs mNF-SCPL. *, #, or + p < 0.05; **, ##, or ++ p < 0.01; ***, ###, or +++ p < 0.001; ****, ####, or ++++ p < 0.0001.